Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4499595 | 0.90 | KDR (0.38) | LIPEHRH3 | |
| SCHEMBL4502936 | 0.89 | LIPE (0.41) | LIPEKCNH2SCN5ASCN9AP2RX3 | |
| SCHEMBL5334942 | 0.89 | LIPE (0.41) | LIPEKCNH2SCN5ASCN9AP2RX3 | |
| SCHEMBL13854944 | 0.88 | LIPE (0.42) | LIPEHRH3KCNH2SCN5ASCN9A | |
| SCHEMBL4507577 | 0.83 | RAB9A (0.52) | HRH3CHRNB4CHRNA3 | |
| SCHEMBL4506585 | 0.82 | PDE10A (0.42) | — | |
| SCHEMBL4511519 | 0.82 | PDE10A (0.42) | — | |
| SCHEMBL4240879 | 0.81 | LIPE (0.40) | LIPEKCNH2SCN5ASCN9AP2RX3 | |
| SCHEMBL4508563 | 0.80 | SCN9A (0.36) | LIPEHRH3SCN9A | |
| SCHEMBL4233527 | 0.79 | KDR (0.40) | LIPEHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-13 | — | — | US | claimed |
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-13 | — | — | US | disclosed |
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-13 | — | — | US | disclosed |
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-13 | — | — | US | disclosed |
| WO-2007029062-A2 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007029062-A2 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | CYP3A4, CYP4B1, CYP3A5 | LIPE 4866/4885HRH3 1682/4885KCNH2 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.